Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $38.50.

ALGS has been the topic of a number of analyst reports. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Finally, Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a research report on Friday, September 25th.

Aligos Therapeutics Trading Down 9.8%

Shares of ALGS stock opened at $4.86 on Monday. Aligos Therapeutics has a 1 year low of $3.98 and a 1 year high of $13.69. The stock has a 50 day simple moving average of $5.96 and a 200 day simple moving average of $5.95.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.95. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. The firm had revenue of $27.78 million for the quarter, compared to analyst estimates of $24.68 million. On average, equities research analysts expect that Aligos Therapeutics will post -6.81 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Several large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after acquiring an additional 216,646 shares in the last quarter. SummitTX Capital L.P. boosted its stake in shares of Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares during the period. Finally, Rockefeller Capital Management L.P. increased its stake in shares of Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases and other viral infections. The company’s research programs are designed to address significant unmet needs in conditions including chronic hepatitis B virus (HBV) infection, hepatitis D virus (HDV) infection and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis.

Aligos’ pipeline includes investigational therapies intended to target different stages of disease biology.